Angiopoietin-like proteins in atherosclerosis

Liu, Yizhang; Zhang, Chi; Jiang, Jie-Feng; Cheng, Zhe-Bin; Zhou, Zhengyang; Tang, Mu-Yao; Sun, Jia-Xiang; Huang, Liang

doi:10.1016/j.cca.2021.06.024

Cited by 13 publications

(8 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, we also observed the overexpression of an angiopoietin gene family, including angiopoietin-like protein 4 (Angptl4) and Angpt2. Angptl4 is already reported as a prognostic marker for ischemic stroke because higher levels of Angptl4 in the plasma were associated with poor prognosis in acute ischemic stroke patients and were a predictive biomarker in atherosclerosis [ 21 , 22 ]. Many clinical studies have suggested using Angptl4 for post-stroke treatment because it could enhance angiogenesis and neurogenesis by reducing neuronal death and inflammatory response [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

Comparative transcriptome findings reveal the neuroinflammatory network and potential biomarkers to early detection of ischemic stroke

et al. 2023

View full text Add to dashboard Cite

Introduction Ischemic stroke accounts for 70–80% of all stroke cases, leading to over two million people dying every year. Poor diagnosis and late detection are the major causes of the high death and disability rate. Methods In the present study, we used the middle cerebral artery occlusion (MCAO) rat model and applied comparative transcriptomic analysis, followed by a systematic advanced bioinformatic analysis, including gene ontology enrichment analysis and Ingenuity Pathway Analysis (IPA). We aimed to identify novel biomarkers for the early detection of ischemic stroke. In addition, we aimed to delineate the molecular mechanisms underlying the development of ischemic stroke, in which we hoped to identify novel therapeutic targets for treating ischemic stroke. Results In the comparative transcriptomic analysis, we identified 2657 differentially expressed genes (DEGs) in the brain tissue of the MCAO model. The gene enrichment analysis highlighted the importance of these DEGs in oxygen regulation, neural functions, and inflammatory and immune responses. We identified the elevation of angiopoietin-2 and leptin receptor as potential novel biomarkers for early detection of ischemic stroke. Furthermore, the result of IPA suggested targeting the inflammasome pathway, integrin-linked kinase signaling pathway, and Th1 signaling pathway for treating ischemic stroke. Conclusion The results of the present study provide novel insight into the biomarkers and therapeutic targets as potential treatments of ischemic stroke.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative transcriptome findings reveal the neuroinflammatory network and potential biomarkers to early detection of ischemic stroke

et al. 2023

View full text Add to dashboard Cite

show abstract

“…LECT2 may enhance atherosclerotic inflammatory response in endothelial cells through CD209 receptor-mediated JNK phosphorylation ( 113 ). ANGPT3, ANGPTL4 and ANGPTL8 can induce endothelial dysfunction and promote dyslipidemia by suppressing the LPL activity, which is associated with a higher risk of atherosclerosis ( 114 ). Contrary to other hepatokines, FGF21 has anti-atherosclerotic properties by inducing adiponectin production in adipocytes and by reducing cholesterol biosynthesis through inhibiting hepatic SREBP2 expression ( 115 ).…”

Section: Metabolic Organ-secreted Factors Linking Nafld To Cvdmentioning

confidence: 99%

The regulatory role of metabolic organ-secreted factors in the nonalcoholic fatty liver disease and cardiovascular disease

Sun

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is a chronic metabolic disease characterized by an excessive accumulation of fat in the liver, which is becoming a major global health problem, affecting about a quarter of the population. In the past decade, mounting studies have found that 25%–40% of NAFLD patients have cardiovascular disease (CVD), and CVD is one of the leading causes of death in these subjects. However, it has not attracted enough awareness and emphasis from clinicians, and the underlying mechanisms of CVD in NAFLD patients remain unclear. Available research reveals that inflammation, insulin resistance, oxidative stress, and glucose and lipid metabolism disorders play indispensable roles in the pathogenesis of CVD in NAFLD. Notably, emerging evidence indicates that metabolic organ-secreted factors, including hepatokines, adipokines, cytokines, extracellular vesicles, and gut-derived factors, are also involved in the occurrence and development of metabolic disease and CVD. Nevertheless, few studies have focused on the role of metabolic organ-secreted factors in NAFLD and CVD. Therefore, in this review, we summarize the relationship between metabolic organ-secreted factors and NAFLD as well as CVD, which is beneficial for clinicians to comprehensive and detailed understanding of the association between both diseases and strengthen management to improve adverse cardiovascular prognosis and survival.

show abstract

“…Z et al, 2021 ). The plasma level of ANGPTL7 is also elevated in obese subjects and is positively associated with TG level, suggesting ANGPTL7 may be explored as a therapeutic target for modulating TG metabolism ( Abu-Farha et al, 2017 ; Liu Y. Z et al, 2021 ).…”

Section: Emerging Targets For Lowering Triglyceridementioning

confidence: 99%

“…ANGPTL5 is primarily expressed in adipose tissue and heart. This protein is positively associated with obesity, type 2 diabetes, oxidized LDL, and especially glucose metabolism disorders, suggesting ANGPTL5 is involved in modulation of TG and glucose homeostasis ( Alghanim et al, 2019 ; Hammad et al, 2020 ; Liu Y. Z et al, 2021 ).…”

Section: Emerging Targets For Lowering Triglyceridementioning

confidence: 99%

Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis

Zhang

Yin

Qiao

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is still the leading cause of death globally, and atherosclerosis is the main pathological basis of CVDs. Low-density lipoprotein cholesterol (LDL-C) is a strong causal factor of atherosclerosis. However, the first-line lipid-lowering drugs, statins, only reduce approximately 30% of the CVD risk. Of note, atherosclerotic CVD (ASCVD) cannot be eliminated in a great number of patients even their LDL-C levels meet the recommended clinical goals. Previously, whether the elevated plasma level of triglyceride is causally associated with ASCVD has been controversial. Recent genetic and epidemiological studies have demonstrated that triglyceride and triglyceride-rich lipoprotein (TGRL) are the main causal risk factors of the residual ASCVD. TGRLs and their metabolites can promote atherosclerosis via modulating inflammation, oxidative stress, and formation of foam cells. In this article, we will make a short review of TG and TGRL metabolism, display evidence of association between TG and ASCVD, summarize the atherogenic factors of TGRLs and their metabolites, and discuss the current findings and advances in TG-lowering therapies. This review provides information useful for the researchers in the field of CVD as well as for pharmacologists and clinicians.

show abstract

Angiopoietin-like proteins in atherosclerosis

Cited by 13 publications

References 80 publications

Comparative transcriptome findings reveal the neuroinflammatory network and potential biomarkers to early detection of ischemic stroke

Comparative transcriptome findings reveal the neuroinflammatory network and potential biomarkers to early detection of ischemic stroke

The regulatory role of metabolic organ-secreted factors in the nonalcoholic fatty liver disease and cardiovascular disease

Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis

Contact Info

Product

Resources

About